PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
2.63
Below 0.5x CRVO's 5.51. Michael Burry might see potential near-term liquidity strain.
2.63
Below 0.5x CRVO's 5.51. Michael Burry might foresee solvency or liquidity crises in a downturn.
2.58
0.5–0.75x CRVO's 5.04. Martin Whitman would question if short-term obligations are too high relative to cash.
No Data
No Data available this quarter, please select a different quarter.
-221.01
Negative short-term coverage while CRVO shows 0.00. Joel Greenblatt would look for cash flow improvements and refinancing catalysts.